Sutro Biopharma, Inc. (STRO) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Sutro Biopharma, Inc. (STRO) Earnings Overview
As of July 8, 2026, Sutro Biopharma, Inc. (STRO) reported trailing twelve-month net income of -$154M, reflecting +24.0% year-over-year growth. The company earned $-11.74 per diluted share over the past four quarters, with a net profit margin of -186.5%.
Looking at the long-term picture, STRO's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2016.
Sutro Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), BOLT (-$30M net income, -433.7% margin), NKTR (-$158M net income, -297.1% margin), STRO has room to improve margins relative to the peer group. Compare STRO vs RCUS →
STRO Earnings vs Peers
Earnings metrics vs comparable public companies
STRO Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$191M | +16.0% | -$105M | $-22.49 | -186.5% | -102.4% |
| 2024 | -$227M | -113.0% | -$238M | $-29.60 | -366.6% | -384.3% |
| 2023 | -$107M | +10.4% | -$89M | $-17.80 | -69.5% | -58.1% |
| 2022 | -$119M | -12.9% | -$129M | $-23.50 | -175.9% | -190.3% |
| 2021 | -$106M | -228.5% | -$99M | $-22.90 | -170.6% | -159.2% |
| 2020 | -$32M | +42.4% | -$71M | $-9.90 | -75.2% | -166.3% |
| 2019 | -$56M | -57.8% | -$55M | $-24.30 | -130.4% | -129.8% |
| 2018 | -$35M | -79.4% | -$37M | $-15.40 | -91.9% | -96.9% |
| 2017 | -$20M | -1256.8% | -$19M | $-28.10 | -38.1% | -37.2% |
| 2016 | $2M | - | $1M | $38.60 | 2.8% | 2.3% |
Download Data
Export STRO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
STRO — Frequently Asked Questions
Quick answers to the most common questions about buying STRO stock.
What is STRO earnings per share (EPS)?
STRO trailing twelve-month (TTM) diluted EPS is $-11.74, reflecting +24.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Sutro Biopharma, Inc.'s net income?
Sutro Biopharma, Inc. (STRO) trailing twelve-month net income is $-154M as of 2025. Earnings grew +24.0% year-over-year.
Is STRO profitable?
STRO is not currently profitable on a TTM basis, reporting a net loss of $-154M. Net margin is -186.5%. Investors should monitor for a return to profitability.
What is STRO's earnings growth rate?
STRO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are STRO's profit margins?
Sutro Biopharma, Inc. net profit margin is -186.5%, operating margin is -102.4%, and gross margin is +92.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is STRO growing earnings?
Yes, STRO earnings are accelerating — EPS growth of +24.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-154M. Earnings momentum is strengthening.
What was STRO's best earnings year?
Sutro Biopharma, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were STRO's earnings last quarter?
STRO's most recent reported quarter was Q1 2026. Net income was $-38M with diluted EPS of $-2.94. For a full breakdown of all quarters, see the quarterly earnings table on this page.